RxDoctor Payments Data

Amanda Smith, MD

Internal Medicine · Lexington, KYNPI 1952541203

Payments from drug & device makers

$1,582in general payments, 2019–2025

Across 85 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$564
  • Pfizer$190
  • Exact Sciences$90
  • Biomerieux Inc$70
  • Astellas Pharma US Inc$56
  • Abbott$50
  • plus $563 from 20 others

What the payments were for

  • Food & beverage$1,582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,582 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$39,033
Medicare patients
88
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$65,010
JardianceEmpagliflozin32$39,220
RelistorMethylnaltrexone Bromide12$28,623
XareltoRivaroxaban23$23,391
EliquisApixaban11$17,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,653
FarxigaDapagliflozin Propanediol13$13,779
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,657
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$2,172
Levothyroxine Sodium132$1,348
SynthroidLevothyroxine Sodium19$1,117
Atorvastatin Calcium152$1,069
Rosuvastatin Calcium37$896
Losartan Potassium110$779
Lisinopril134$758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$564$65,01045 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$32$28,62312 claims
PfizerEliquis$190$17,16811 claims
AstraZenecaFarxiga$29$13,77913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$46$1,348132 claims
AbbVieSynthroid$33$1,11719 claims
Lilly USA, LLCOlanzapine$47$37315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →